Dr. Bart K. Chwalisz: A 30-year-old woman was evaluated in the neuro-ophthalmology clinic at a hospital affiliated with this hospital because of monocular vision loss. Two months before the current ...

Please provide your email address to receive an email when new articles are posted on . A 63-year-old woman was referred to the neuro-ophthalmology service at the New England Eye Center for evaluation ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The phase 2 ACUITY trial met its primary safety endpoint ...

—A large data analysis found a significantly heightened relative risk of optic neuritis in NMOSD, MOGAD, and other inflammatory diseases, supporting prompt evaluation of visual complaints in these ...

Ophthalmic diseases specialist Oculis Holding AG announced positive phase II data showing its serum-glucose corticoid kinase-2 activator OCS-05 protected nerve cells and improved vision in patients ...

Visual changes can often be a symptom of a neurological condition, such as stroke, migraine, or an infection. In some cases, changes may be permanent or progressive, but in many cases, prompt ...

OCS-05 demonstrates safety and efficacy in treating acute optic neuritis, receiving FDA IND clearance for clinical development in the U.S. Small sample size of only 36 patients in the Phase 2 ACUITY ...

Riad Sherif, M.D., Chief Executive Officer of Oculis, commented: “It is a privilege to collaborate with Pitié-Salpêtrière Hospital, a world-renowned center for modern neurology, on the Phase 2 ACUITY ...